Pancreatic cancer cells express 25-hydroxyvitamin D-1α-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3

Carcinogenesis

Volumn 25, Issue 6, 2004, Pages 1015-1026

  Schwartz, Gary G ^a   Eads, Dawn ^a   Rao, Anuradha ^a   Cramer, Scott D ^a   Willingham, Mark C ^a   Chen, Tai C ^b   Jamieson, Daniel P ^b   Wang, Lilin ^b   Burnstein, Kerry L ^c   Holick, Michael F ^b   Koumenis, Constantinos ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIFEDIOL; CYCLIN DEPENDENT KINASE INHIBITOR; K RAS PROTEIN; OXYGENASE; PROTEIN P21; PROTEIN P27; CYTOCHROME P450; MESSENGER RNA; PRIMER DNA; STEROID MONOOXYGENASE; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ALLELE; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INDUCTION; GENE MUTATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITION KINETICS; MEDICAL DECISION MAKING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL DIVISION; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

BASE SEQUENCE; CALCIFEDIOL; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HUMANS; PANCREATIC NEOPLASMS; RNA, MESSENGER; STEROID HYDROXYLASES;

EID: 3042819559     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgh086     Document Type: Article

References (56)

1. Ahlgren,J.D. (1996) Epidemiology and risk factors in pancreatic cancer. Semin. Oncol., 23, 241-250.
2. Li,D. (2001) Molecular epidemiology of pancreatic cancer. Cancer J., 7, 259-265.
3. Rosemurgy,A.S. and Serafini,F.M. (2000) New directions in systemic therapy of pancreatic cancer. Cancer Control, 7, 437-451.
4. Douglass,H.O.,Jr (1995) Adjuvant therapy for pancreatic cancer. World J. Surg., 19, 270-274.
5. Rosemurgy,A.S. and Serafini,F.M. (2000) New directions in systemic therapy of pancreatic cancer. Cancer Control, 7, 437-451.
6. Leszczyniecka,M., Roberts,T., Dent,P., Grant,S. and Fisher,P.B. (2001) Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol. Ther., 90, 105-156.
7. Borden,E.C., Lotan,R., Levens,D., Young,C.W. and Waxman,S. (1993) Differentiation therapy of cancer: laboratory and clinical investigations. Cancer Res., 53, 4109-4115.
8. Studzinski,G.P., McLane,J.A. and Uskokovic,M.R. (1993) Signaling pathways for vitamin D-induced differentiation: implications for therapy of proliferative and neoplastic diseases. Crit. Rev. Eukaryot. Gene Expr., 3, 279-312.
9. Polek,T.C. and Weigel,N.L. (2002) Vitamin D and prostate cancer. J. Androl., 23, 9-17.
10. Feldman,D., Zhao,X.Y. and Krishnan,A.V. (2000) Vitamin D and prostate cancer [editorial; comment]. Endocrinology, 141, 5-9.
11. Miller,W.H.,Jr (1998) The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer, 83, 1471-1482.
12. Gottardis,M.M., Lamph,W.W., Shalinsky,D.R., Wellstein,A. and Heyman,R.A. (1996) The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res. Treat., 38, 85-96.
13. Chen,Z., Chen,S.J. and Wang,Z.Y. (1994) Retinoic acid and acute promyelocytic leukemia: a model of targeting treatment for human cancer. C. R. Acad. Sci. III, 317, 1135-1141.
14. Blutt,S.E., McDonnell,T.J., Polek,T.C. and Weigel,N.L. (2000) Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2 [see comments]. Endocrinology, 141, 10-17.
15. Ravid,A., Rocker,D., Machlenkin,A., Rotem,C., Hochman,A., Kessler-Icekson,G., Liberman,U.A. and Koren,R. (1999) 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res., 59, 862-867.
16. Sundaram,S. and Gewirtz,D.A. (1999) The vitamin D3 analog EB 1089 enhances the response of human breast tumor cells to radiation. Radiat. Res., 152, 479-486.
17. Weisman,R.A., Christen,R., Los,G. et al. (1998) Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism. Otolaryngol. Head Neck Surg., 118, 597-602.
18. Ryu,S., Stein,J.P., Chung,C.T., Lee,Y.J. and Kim,J.H. (2001) Enhanced apoptosis and radiosensitization by combined 13-cis-retinoic acid and interferon-alpha2a; role of RAR-beta gene. Int. J. Radiat. Oncol. Biol. Phys., 51, 785-790.
19. Siwinska,A., Opolski,A., Chrobak,A., Wietrzyk,J., Wojdat,E., Kutner,A., Szelejewski,W. and Radzikowski,C. (2001) Potentiation of the antiproliferative effect in vitro of doxorubicin, cisplatin and genistein by new analogues of vitamin D. Anticancer Res., 21, 1925-1929.
20. Moffatt,K.A., Johannes,W.U. and Miller,G.J. (1999) 1Alpha, 25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin. Cancer Res., 5, 695-703.
21. Holmes,F.A. (1996) Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Semin. Oncol., 23, 46-56.
22. Guyton,K.Z., Kensler,T.W. and Posner,G.H. (2001) Cancer chemoprevention using natural vitamin D and synthetic analogs. Annu. Rev. Pharmacol. Toxicol., 41, 421-442.
23. Hansen,C.M., Hamberg,K.J., Binderup,E. and Binderup,L. (2000) Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharm. Des., 6, 803-828.
24. Evans,T.R., Colston,K.W., Lofts,F.J., Cunningham,D., Anthoney,D.A., Gogas,H., de Bono,J.S., Hamberg,K.J., Skov,T. and Mansi,J.L. (2002) A phase II trial of the vitamin D analogue Seocalcitol (EB 1089) in patients with inoperable pancreatic cancer. Br. J. Cancer, 86, 680-685.
25. Kawa,S., Yoshizawa,K., Tokoo,M., Imai,H., Oguchi,H., Kiyosawa,K., Homma,T., Nikaido,T. and Furihata,K. (1996) Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines. Gastroenterology, 110, 1605-1613.
26. Kawa,S., Nikaido,T., Aoki,Y., Zhai,Y., Kumagai,T., Furihata,K., Fujii,S. and Kiyosawa,K. (1997) Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer, 76, 884-889.
27. Colston,K.W., James,S.Y., Ofori-Kuragu,E.A., Binderup,L. and Grant,A.G. (1997) Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro. Br. J. Cancer, 76, 1017-1020.
28. Pettersson,F., Colston,K.W. and Dalgleish,A.G. (2000) Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. Br. J. Cancer, 83, 239-245.
29. Schwartz,G.G., Whitlatch,L.W., Chen,T.C., Lokeshwar,B.L. and Holick,M.F. (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxy D3. Cancer Epidemiol. Biomarkers Prev., 7, 391-395.
30. Barreto,A.M., Schwartz,G.G., Woodruff,R. and Cramer,S.D. (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells [In Process Citation]. Cancer Epidemiol. Biomarkers Prev., 9, 265-270.
31. Scarpa,A., Capelli,P., Villaneuva,A., Zamboni,G., Lluis,F., Accolla,R., Mariuzzi,G. and Capella,G. (1994) Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. Int. J. Cancer, 57, 167-171.
32. Chen,T.C., Schwartz,G.G., Burnstein,K.L., Lokeshwar,B.L. and Holick,M.F. (2000) The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer [In Process Citation]. Clin. Cancer Res., 6, 901-908.
33. Whitlatch,L.W., Young,M.V., Schwartz,G.G., Flanagan,J.N., Burnstein,K.L., Lokeshwar,B.L., Rich,E.S., Holick,M.F. and Chen,T.C. (2002) 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol., 81, 135-140.
34. Campbell,M.J., Elstner,E., Holden,S., Uskokovic,M. and Koeffler,H.P. (1997) Inhibition of proliferation of prostate cancer cells by a 19-norhexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. J. Mol. Endocrinol., 19, 15-27.
35. Verlinden,L., Verstuyf,A., Convents,R., Marcelis,S., Van Camp,M. and Bouillon,R. (1998) Action of 1,25 (OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol. Cell Endocrinol., 142, 57-65.
36. Liu,M., Lee,M.H., Cohen,M., Bommakanti,M. and Freedman,L.P. (1996) Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev., 10, 142-153.
37. Bardeesy,N. and DePinho,R.A. (2002) Pancreatic cancer biology and genetics. Nature Rev. Cancer, 2, 897-909.
38. Cross,H.S., Bareis,P., Hofer,H., Bischof,M.G., Bajna,E., Kriwanek,S., Bonner,E. and Peterlik,M. (2001) 25-Hydroxyvitamin D (3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids, 66, 287-292.
39. Schuessler,M., Astecker,N., Herzig,G., Vorisek,G. and Schuster,I. (2001) Skin is an autonomous organ in synthesis, two-step activation and degradation of vitamin D (3): CYP27 in epidermis completes the set of essential vitamin D (3)-hydroxylases. Steroids, 66, 399-408.
40. Hewison,M., Zehnder,D., Bland,R. and Stewart,P.M. (2000) 1alpha-Hydroxylase and the action of vitamin D. J. Mol. Endocrinol., 25, 141-148.
41. Zehnder,D., Bland,R., Williams,M.C., McNinch,R.W., Howie,A.J., Stewart,P.M. and Hewison,M. (2001) Extrarenal expression of 25-hydroxyvitamin D (3)-1 alpha-hydroxylase. J Clin. Endocrinol. Metab., 86, 888-894.
42. Meszoely,I.M., Means,A.L., Scoggins,C.R. and Leach,S.D. (2001) Developmental aspects of early pancreatic cancer. Cancer J., 7, 242-250.
43. Hsu,J.Y., Feldman,D., McNeal,J.E. and Peehl,D.M. (2001) Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res., 61, 2852-2856.
44. Bland,R., Walker,E.A., Hughes,S.V., Stewart,P.M. and Hewison,M. (1999) Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D metabolism by calcium. Endocrinology, 140, 2027-2034.
45. Hughes,M.R., Baylink,D.J., Jones,P.G. and Haussler,M.R. (1976) Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3. J. Clin. Invest., 58, 61-70.
46. Huang,D.C., Papavasiliou,V., Rhim,J.S., Horst,R.L. and Kremer,R. (2002) Targeted disruption of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in ras-transformed keratinocytes demonstrates that locally produced 1alpha,25-dihydroxyvitamin D3 suppresses growth and induces differentiation in an autocrine fashion. Mol. Cancer Res., 1, 56-67.
47. Moffatt,K.A., Johannes,W.U., Hedlund,T.E. and Miller,G.J. (2001) Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D (3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res., 61, 7122-7129.
48. Hager,G., Formanek,M., Gedlicka,C., Thurnher,D., Knerer,B. and Kornfehl,J. (2001) 1,25 (OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol., 121, 103-109.
49. Seol,J.G., Park,W.H., Kim,E.S., Jung,C.W., Binderup,L., Koeffler,H.P., Kim,B.K. and Lee,Y.Y. (2000) Effect of a novel vitamin D3 analog, EB1089, on G1 cell cycle regulatory proteins in HL-60 cells. Int. J. Oncol., 16, 315-320.
50. Wang,Q.M., Chen,F., Luo,X., Moore,D.C., Flanagan,M. and Studzinski,G.P. (1998) Lowering of p27Kip1 levels by its antisense or by development of resistance to 1,25-dihydroxyvitamin D3 reverses the G1 block but not differentiation of HL60 cells. Leukemia, 12, 1256-1265.
51. Wade,W.N., Willingham,M.C., Koumenis,C. and Cramer,S.D. (2002) p27Kip1 is essential for the antiproliferative action of 1,25-dihydroxyvitamin D3 in primary, but not immortalized, mouse embryonic fibroblasts. J. Biol. Chem., 277, 37301-37306.
52. Solomon,C., Kremer,R., White,J.H. and Rhim,J.S. (2001) Vitamin D resistance in RAS-transformed keratinocytes: mechanism and reversal strategies. Radiat. Res., 155, 156-162.
53. Solomon,C., Sebag,M., White,J.H., Rhim,J. and Kremer,R. (1998) Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes. J. Biol. Chem., 273, 17573-17578.
54. Walsh,A.B. and Bar-Sagi,D. (2001) Differential activation of the Rac pathway by Ha-Ras and K-Ras. J. Biol. Chem., 276, 15609-15615.
55. Matallanas,D., Arozarena,I., Berciano,M.T., Aaronson,D.S., Pellicer,A., Lafarga,M. and Crespo,P. (2003) Differences on the inhibitory specificities of H-Ras, K-Ras and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J. Biol. Chem., 278, 4572-4581.
56. Xue,L., Lipkin,M., Newmark,H. and Wang,J. (1999) Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. J. Natl Cancer Inst., 91, 176-181.